ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0791

Optimizing Knee Osteoarthritis Treatment with the Precision Medicine Approach in a Clinical Trial Dataset

Caroline Walton1, Forrest Hurley2, Liubov Arbeeva3, Stephen Messier4, Shannon Mihalko4, Jeffrey Katz5, Richard Loeser6, David Hunter7, Leigh Callahan8 and Amanda Nelson2, 1UNC School of Medicine, Chapel Hill, NC, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3University of North Carolina, Chapel Hill, Carrboro, NC, 4Wake Forest University, Winston Salem, NC, 5Brigham and Women's Hospital, Brookline, MA, 6University of North Carolina, Chapel Hill, NC, 7Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, 8University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC

Meeting: ACR Convergence 2024

Keywords: Osteoarthritis, Outcome measures, pain

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: Osteoarthritis – Clinical Trials

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: Precision medicine has previously identified subgroups of clinical trial participants with knee osteoarthritis (kOA) that benefit more from a specific intervention than others. We used a precision medicine approach in the Weight-Loss and Exercise for Communities with Arthritis in North Carolina (WE-CAN) data set comparing a diet and exercise intervention to an attention control to determine the optimal treatment regimen targeting WOMAC pain score in specific participants with kOA and overweight/obesity.

Methods: We used a subset of 645 out of 823 participants (i.e., those who were not missing outcome data) in the WE-CAN data set who were randomly assigned to either a diet and exercise intervention or an attention control (healthy lifestyle education group sessions) for 18 months (PMID 36511925). Based on clinical judgement and prior analyses of optimal kOA interventions, we selected baseline features, including demographics, physical features, WOMAC subscales, activity level, and comorbidities, which are included in Table 1. These were entered into 5 machine learning models and 2 fixed treatment models (zero-order models). Individualized treatment rules (ITRs) were estimated for change in WOMAC pain score at 18 months, and value functions were calculated for each ITR. A higher value function indicated a higher quality of the estimated ITR, signifying more benefit to future patients based on predicted WOMAC pain scores. Validation methods for this study included cross-validation and Jackknife Estimator.

Results: The average (standard deviation) age of participants was 65.3 (7.7) years, and the mean BMI was 36.3 (6.4) kg/m2 (Table 1). Most participants were women (76.6%), and most had co-morbidities, including obesity, hypertension, and arthritis in other joints. A smaller proportion had diabetes and/or cardiovascular disease. On a scale of 1-20, with larger numbers indicating more severe pain, the average baseline WOMAC pain score was 7.4.

Value functions for each machine learning model regarding change in WOMAC pain scores are shown in Table 2. Placing all participants in the Diet and Exercise group (zero-order model) was among the highest value functions. We found no statistically significant subgroups that would benefit more from the alternative treatment (attention control).

Conclusion: In the WE-CAN study, precision medicine models found no significant improvement (i.e., small differences in value functions and overlapping confidence intervals) in pain scores over treating all participants with kOA with both diet and exercise. This supports the utility of the diet and exercise intervention in all patients with symptomatic kOA and overweight/obesity. Future work will evaluate additional features (depression and self-efficacy) and alternative outcomes, such as change in SF-36 physical component score, weight, WOMAC function/stiffness scores, compressive force, and plasma IL-6. The WE-CAN data set compared diet and exercise to an attention control group; therefore, the efficacy of precision models to predict response to alternative treatment options such as diet or exercise alone should continue to be researched in this and other studies.

Supporting image 1

Supporting image 2


Disclosures: C. Walton: None; F. Hurley: None; L. Arbeeva: None; S. Messier: None; S. Mihalko: None; J. Katz: None; R. Loeser: None; D. Hunter: Novartis, 2, TLC, 2; L. Callahan: None; A. Nelson: MedScape Education, 6, NestleHealth, 6.

To cite this abstract in AMA style:

Walton C, Hurley F, Arbeeva L, Messier S, Mihalko S, Katz J, Loeser R, Hunter D, Callahan L, Nelson A. Optimizing Knee Osteoarthritis Treatment with the Precision Medicine Approach in a Clinical Trial Dataset [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/optimizing-knee-osteoarthritis-treatment-with-the-precision-medicine-approach-in-a-clinical-trial-dataset/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/optimizing-knee-osteoarthritis-treatment-with-the-precision-medicine-approach-in-a-clinical-trial-dataset/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology